CEO Andrew Robbins was paid $27,762,684 in fiscal year 2025, ↑ up 464.5% from fiscal year 2024, the 99th percentile of its disclosed peer group (SEC filing 0001193125-26-173834 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$27,762,684 ↑ Andrew Robbins total, FY2025 | 99th CEO pay percentile vs peers | 95:1 CEO-to-median pay ratio | 90.24% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
COGT's next annual pay disclosure, estimated April 24, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Andrew Robbins | $724,554 | $21,600 | $12,993,250 | $13,447,680 | $561,600 | $0 | $14,000 | $27,762,684 |
| Chief Executive Officer, President and Director | ||||||||
| Jessica Sachs | 549,389 | 12,342 | 4,535,250 | 3,746,304 | 320,892 | 0 | 14,000 | 9,178,177 |
| Chief Medical Officer | ||||||||
| John Robinson | 532,035 | 11,952 | 4,535,250 | 3,746,304 | 310,756 | 0 | 14,000 | 9,150,297 |
| Chief Scientific Officer | ||||||||
| Cole Pinnow | 482,266 | 9,568 | 4,535,250 | 3,549,696 | 248,768 | 0 | 14,000 | 8,839,548 |
| Chief Commercial Officer | ||||||||
| John Green | 510,677 | 11,467 | 3,965,750 | 3,746,304 | 298,131 | 0 | 14,000 | 8,546,329 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Andrew Robbins | $27,762,684 | $4,917,890 | $7,898,772 | ↑ +22,844,794 |
| Jessica Sachs | 9,178,177 | 1,832,714 | 2,999,941 | ↑ +7,345,463 |
| John Robinson | 9,150,297 | 1,807,431 | 2,975,911 | ↑ +7,342,866 |
| Cole Pinnow | 8,839,548 | 3,969,744 | — | ↑ +4,869,804 |
| John Green | 8,546,329 | 1,747,767 | — | ↑ +6,798,562 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Cogent Biosciences, Inc.'s Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper COGT reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
Get the Cogent Biosciences, Inc. Peer Teardown Report
$27,762,684 Andrew Robbins total, FY2025
$199
The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.
Data as of October 5, 2026 · Source: 0001193125-26-173834 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).
Reports for COGT
Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:
Order COGT
Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.
How we handle your data → Privacy
Each company listed discloses COGT in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named COGT in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Get the Cogent Biosciences, Inc. Executive Compensation Report
$1,500
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2025 total |
|---|---|---|
| Andrew Robbins | CEO | $27,762,684 |
| Cole Pinnow | CCO | $8,839,548 |
| Jessica Sachs | Chief Medical Officer | $9,178,177 |
| John Green | CFO | $8,546,329 |
| John Robinson | Chief Scientific Officer | $9,150,297 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Arlene M. Morris | Independent Director | $254,615 |
| Chris Cain | Independent Director | $252,115 |
| Karen Ferrante | Independent Director | $247,115 |
| Matthew E. Ros | Independent Director | $244,615 |
| Peter Harwin | Chair of the Board | $277,115 |
| Todd Shegog | Independent Director | $257,115 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Andrew Robbins | Director | 2026-05-19 | A | 160,000 | $0 | $0 | Common | Form 4 ↗ |
| Andrew Robbins | Director | 2026-05-19 | D | 160,000 | 0 | 0 | Common | Form 4 ↗ |
| Matthew E. Ros | Director | 2026-06-09 | A | 17,901 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Todd Shegog | Director | 2026-06-09 | A | 17,901 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Chris Cain | Director | 2026-06-09 | A | 17,901 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Karen Ferrante | Director | 2026-06-09 | A | 17,901 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Arlene M. Morris | Director | 2026-06-09 | A | 17,901 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Peter Harwin | Director | 2026-06-09 | A | 17,901 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-07-01 | — | 627 | — | — | 1 insider, 1 accrual row | ||
| Arlene M. Morris | Director | 2026-08-27 | D | 41,927 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Arlene M. Morris | Director | 2026-08-27 | D | 3,161 | 38 | 118,663 | Common, open-market sale | Form 4 ↗ |
| Arlene M. Morris | Director | 2026-08-27 | D | 42,349 | 37 | 1,570,830 | Common, open-market sale | Form 4 ↗ |
| Arlene M. Morris | Director | 2026-08-27 | D | 3,583 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Arlene M. Morris | Director | 2026-08-27 | A | 3,583 | 3 | 9,029 | Common | Form 4 ↗ |
| Arlene M. Morris | Director | 2026-08-27 | A | 41,927 | 6 | 236,468 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-10-01 | — | 759 | — | — | 1 insider, 1 accrual row | ||
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Andrew Robbins | Director | 2026-05-19 | A | 160,000 | $0 | $0 | Common | Form 4 ↗ |
| Andrew Robbins | Director | 2026-05-19 | D | 160,000 | 0 | 0 | Common | Form 4 ↗ |
| Matthew E. Ros | Director | 2026-06-09 | A | 17,901 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Todd Shegog | Director | 2026-06-09 | A | 17,901 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Chris Cain | Director | 2026-06-09 | A | 17,901 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Karen Ferrante | Director | 2026-06-09 | A | 17,901 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Arlene M. Morris | Director | 2026-06-09 | A | 17,901 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Peter Harwin | Director | 2026-06-09 | A | 17,901 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Karen Ferrante | Director | 2026-07-01 | A | 627 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Arlene M. Morris | Director | 2026-08-27 | D | 41,927 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Arlene M. Morris | Director | 2026-08-27 | D | 3,161 | 38 | 118,663 | Common, open-market sale | Form 4 ↗ |
| Arlene M. Morris | Director | 2026-08-27 | D | 42,349 | 37 | 1,570,830 | Common, open-market sale | Form 4 ↗ |
| Arlene M. Morris | Director | 2026-08-27 | D | 3,583 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Arlene M. Morris | Director | 2026-08-27 | A | 3,583 | 3 | 9,029 | Common | Form 4 ↗ |
| Arlene M. Morris | Director | 2026-08-27 | A | 41,927 | 6 | 236,468 | Common | Form 4 ↗ |
| Karen Ferrante | Director | 2026-10-01 | A | 759 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Jessica Sachs | RSU | 2025-12-17 | — | — | 50,000 | — | $1,972,500 |
| John Green | OPTION | 2025-12-17 | — | — | 65,000 | — | 1,976,832 |
| Andrew Robbins | OPTION | 2025-12-17 | — | — | 245,000 | — | 7,451,136 |
| Cole Pinnow | PSU | 2025-10-01 | — | 225,000 | — | 450,000 | 2,562,750 |
| John Green | PSU | 2025-10-01 | — | 175,000 | — | 350,000 | 1,993,250 |
| John Robinson | OPTION | 2025-01-23 | — | — | 270,000 | — | 1,769,472 |
| John Green | RSU | 2025-12-17 | — | — | 50,000 | — | 1,972,500 |
| John Robinson | RSU | 2025-12-17 | — | — | 50,000 | — | 1,972,500 |
| John Robinson | PSU | 2025-10-01 | — | 225,000 | — | 450,000 | 2,562,750 |
| Andrew Robbins | PSU | 2025-10-01 | — | 500,000 | — | 1,000,000 | 5,695,000 |
| Cole Pinnow | RSU | 2025-12-17 | — | — | 50,000 | — | 1,972,500 |
| Jessica Sachs | OPTION | 2025-01-23 | — | — | 270,000 | — | 1,769,472 |
| Jessica Sachs | PSU | 2025-10-01 | — | 225,000 | — | 450,000 | 2,562,750 |
| Andrew Robbins | RSU | 2025-12-17 | — | — | 185,000 | — | 7,298,250 |
| Cole Pinnow | OPTION | 2025-12-17 | — | — | 65,000 | — | 1,976,832 |
| John Green | OPTION | 2025-01-23 | — | — | 270,000 | — | 1,769,472 |
| Cole Pinnow | OPTION | 2025-01-23 | — | — | 240,000 | — | 1,572,864 |
| John Robinson | OPTION | 2025-12-17 | — | — | 65,000 | — | 1,976,832 |
| Jessica Sachs | OPTION | 2025-12-17 | — | — | 65,000 | — | 1,976,832 |
| Andrew Robbins | OPTION | 2025-01-23 | — | — | 915,000 | — | 5,996,544 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Jessica Sachs | $1,972,500 | $2,562,750 | $3,746,304 | 30.9% |
| John Green | 1,972,500 | 1,993,250 | 3,746,304 | 25.8% |
| Andrew Robbins | 7,298,250 | 5,695,000 | 13,447,680 | 21.5% |
| Cole Pinnow | 1,972,500 | 2,562,750 | 3,549,696 | 31.7% |
| John Robinson | 1,972,500 | 2,562,750 | 3,746,304 | 30.9% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| John Robinson | Option | 156,250 | 4.63 | — |
| John Robinson | Option | 46,667 | 13.63 | — |
| John Robinson | Option | 65,000 | 39.45 | — |
| Cole Pinnow | Option | 65,000 | 39.45 | — |
| John Green | Option | 208,125 | 8.89 | — |
| John Green | Option | 4,687 | 7.6 | — |
| John Green | RSU | 350,000 | — | 12,432,000 |
| Andrew Robbins | Option | 14,375 | 7.6 | — |
| John Robinson | RSU | 50,000 | — | 1,776,000 |
| Jessica Sachs | Option | 208,125 | 8.89 | — |
| Jessica Sachs | Option | 46,667 | 13.63 | — |
| Andrew Robbins | RSU | 1,000,000 | — | 35,520,000 |
| Andrew Robbins | Option | 245,000 | 39.45 | — |
| John Robinson | RSU | 450,000 | — | 15,984,000 |
| John Green | Option | 43,750 | 13.63 | — |
| Andrew Robbins | Option | 572,917 | 4.63 | — |
| Andrew Robbins | RSU | 185,000 | — | 6,571,200 |
| Cole Pinnow | Option | 317,187 | 8.22 | — |
| John Robinson | Option | 208,125 | 8.89 | — |
| Cole Pinnow | Option | 185,000 | 8.89 | — |
| Jessica Sachs | RSU | 50,000 | — | 1,776,000 |
| Cole Pinnow | RSU | 50,000 | — | 1,776,000 |
| John Robinson | Option | 5,208 | 7.6 | — |
| Jessica Sachs | Option | 65,000 | 39.45 | — |
| Jessica Sachs | RSU | 450,000 | — | 15,984,000 |
| Cole Pinnow | RSU | 450,000 | — | 15,984,000 |
| John Green | RSU | 50,000 | — | 1,776,000 |
| John Green | Option | 156,250 | 4.63 | — |
| Jessica Sachs | Option | 156,250 | 4.63 | — |
| Jessica Sachs | Option | 5,208 | 7.6 | — |
| John Green | Option | 65,000 | 39.45 | — |
| Andrew Robbins | Option | 705,312 | 8.89 | — |
| Andrew Robbins | Option | 153,125 | 13.63 | — |
Our executive officer compensation program focuses on attracting, retaining and rewarding executive officers in order to promote our long-term success. In setting compensation levels and designing the elements of our program, we seek to establish overall compensation levels that are internally equitable and competitive with the talent market.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Compensia |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-04-13 | 129,183,846 | 13,977,449 | 32,606 | 90.24% | Passed |
| 2025 | 2025-06-04 | 89,797,699 | 808,715 | 43,931 | 99.11% | Passed |
| 2024 | 2024-06-05 | 69,604,506 | 6,731,575 | 12,281 | 91.18% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-04-13 | 90.24%a |
| 2025 | 2025-06-04 | 99.11%b |
| 2024 | 2024-06-05 | 91.18%c |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes, if any, will not be counted as votes cast on the matters and will have no effect on the outcome of these matters.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes, if any, will not be counted as votes cast on the matter and will have no effect on the outcome of the matter.”.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes, if any, will not be counted as votes cast on the matter and will have no effect on the outcome of the matter.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 95 : 1 |
|---|---|
| CEO total compensation | $27,762,684 |
| Median employee compensation | $292,285 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Peter HarwinIndependent · Board Chair · Nominating · Science | $92,500 | $0 | $184,615 | $0 | $0 | $277,115 |
| Todd ShegogIndependent · Audit (Chair) · Compensation | 72,500 | 0 | 184,615 | 0 | 0 | 257,115 |
| Arlene M. MorrisIndependent · Audit · Compensation (Chair) | 70,000 | 0 | 184,615 | 0 | 0 | 254,615 |
| Chris CainIndependent · Audit · Compensation (Chair) · Science | 67,500 | 0 | 184,615 | 0 | 0 | 252,115 |
| Karen FerranteIndependent · Audit (Chair) · Nominating · Science | 62,500 | 0 | 184,615 | 0 | 0 | 247,115 |
| Matthew E. RosIndependent · Audit · Nominating | 60,000 | 0 | 184,615 | 0 | 0 | 244,615 |
| Andrew RobbinsEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | $184,615 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $425,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $425,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Cogent Biosciences, Inc. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Cogent Biosciences, Inc..
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Cogent Biosciences, Inc. | 2025 | Andrew Robbins | $724,554 | $12,993,250 | $13,447,680 | $561,600 | $27,762,684 |
| 2 | Immunovant, Inc. | 2026 | Eric Venker | 636,618 | 0 | 19,010,639 | 0 | 20,158,767 |
| 3 | SpringWorks Therapeutics, Inc. | 2024 | Saqib Islam | 760,000 | 7,899,760 | 6,689,100 | 798,000 | 16,153,317 |
| 4 | Corcept Therapeutics Incorporated | 2025 | Joseph Belanoff | 1,182,333 | 0 | 12,907,718 | 0 | 15,303,551 |
| 5 | BridgeBio Pharma, Inc. | 2025 | Neil Kumar | 1,044,000 | 10,606,275 | 1,874,992 | 0 | 14,944,585 |
| 6 | Revolution Medicines, Inc. | 2025 | Mark Goldsmith | 812,500 | 3,968,076 | 8,995,114 | 889,700 | 14,672,390 |
| 7 | Blueprint Medicines Corporation | 2024 | Kathryn Haviland | 821,363 | 7,472,480 | 4,315,144 | 854,217 | 13,477,004 |
| 8 | CG Oncology, Inc. | 2025 | Arthur Kuan | 690,000 | 3,451,884 | 7,350,515 | 414,000 | 11,928,401 |
| 9 | Cytokinetics, Incorporated | 2025 | Robert Blum | 853,069 | 5,150,019 | 5,095,918 | 772,715 | 11,881,456 |
| 10 | Crinetics Pharmaceuticals, Inc. | 2025 | R. Scott Struthers | 718,500 | 3,280,540 | 7,160,564 | 462,355 | 11,628,959 |
| 11 | Nuvalent, Inc. | 2025 | James Porter | 652,100 | 4,392,563 | 5,857,906 | 469,512 | 11,393,602 |
| 12 | Apellis Pharmaceuticals, Inc. | 2024 | Cedric Francois | 793,193 | 4,779,832 | 4,787,768 | 0 | 10,957,451 |
| 13 | Kiniksa Pharmaceuticals, Ltd. | 2025 | Sanj Patel | 943,129 | 3,798,021 | 4,743,446 | 1,284,065 | 10,782,661 |
| 14 | Arcus Biosciences, Inc. | 2025 | Terry Rosen | 775,000 | 2,199,450 | 6,008,860 | 658,750 | 9,656,813 |
| 15 | IDEAYA Biosciences, Inc. | 2025 | Yujiro Hata | 700,000 | 0 | 8,418,840 | 378,000 | 9,512,640 |
| 16 | Amicus Therapeutics, Inc. | 2024 | Bradley Campbell | 767,308 | 4,990,365 | 2,105,627 | 0 | 8,526,943 |
| 17 | Immunome, Inc. | 2025 | Clay Siegall | 735,000 | 0 | 6,272,810 | 661,500 | 7,682,601 |
| 18 | Syndax Pharmaceuticals, Inc. | 2025 | Michael Metzger | 754,300 | 2,021,965 | 3,454,360 | 848,588 | 7,089,213 |
| 19 | Day One Biopharmaceuticals, Inc. | 2024 | Jeremy Bender | 680,000 | 2,700,280 | 2,664,697 | 501,800 | 6,560,577 |
| 20 | Arvinas, Inc. | 2025 | John Houston | 706,236 | 2,685,840 | 2,671,051 | 457,000 | 6,534,127 |
| 21 | Bicycle Therapeutics plc | 2025 | Kevin Lee | 862,339 | 1,724,800 | 2,961,297 | 543,642 | 6,341,473 |
| 22 | Allogene Therapeutics, Inc. | 2025 | David Chang | 724,000 | 2,409,537 | 2,588,329 | 400,010 | 6,136,093 |
| 23 | AnaptysBio, Inc. | 2025 | Daniel Faga | 706,011 | 1,592,001 | 3,345,653 | 465,968 | 6,133,943 |
| 24 | Tyra Biosciences, Inc. | 2025 | Todd Harris | 658,000 | 0 | 4,568,037 | 325,710 | 5,566,997 |
| 25 | Xencor, Inc. | 2025 | Bassil Dahiyat | 742,800 | 1,552,892 | 2,727,018 | 490,248 | 5,521,205 |
| 26 | Celldex Therapeutics, Inc. | 2025 | Anthony Marucci | 785,804 | 0 | 4,027,590 | 0 | 5,366,709 |
| 27 | Kura Oncology, Inc. | 2025 | Troy Wilson | 700,000 | 0 | 3,297,250 | 630,000 | 4,735,016 |
| 28 | Relay Therapeutics, Inc. | 2025 | Sanjiv Patel | 707,846 | 0 | 3,513,900 | 424,708 | 4,646,454 |
| 29 | Erasca, Inc. | 2025 | Jonathan Lim | 670,400 | 0 | 3,135,250 | 482,688 | 4,298,838 |
| 30 | IGM Biosciences, Inc. | 2023 | Fred Schwarzer | 646,797 | 868,050 | 1,336,743 | 355,738 | 3,207,328 |
| 31 | Iovance Biotherapeutics, Inc. | 2025 | Frederick Vogt | 800,000 | 759,375 | 0 | 312,000 | 1,888,175 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Cogent Biosciences, Inc. | 135% | not disclosed | No | Compensia |
| Allogene Therapeutics, Inc. | not disclosed | Option 55 · RSU 25 · PSU 20 | not disclosed | Compensia |
| Amicus Therapeutics, Inc. | not disclosed | Option 33 · RSU 33 · PRSU 33 | Yes — TSR Goal | Pay Governance |
| AnaptysBio, Inc. | 110% | not disclosed | No | Alpine Rewards |
| Apellis Pharmaceuticals, Inc. | 90.74% | RSU 50 · PSU 50 | not disclosed | Pay Governance |
| Arcus Biosciences, Inc. | 100% | Options 67 · RSU 33 | not disclosed | Radford |
| Arvinas, Inc. | 108% | Options 50 · RSU 50 | not disclosed | Aon (Aon's Human Capital Solutions practice, a division of Aon plc) |
| Bicycle Therapeutics plc | 97% | not disclosed | not disclosed | not disclosed |
| Blueprint Medicines Corporation | 130% | RSU 37 · Options 32 · PSU 31 | Yes — Relative Total Stockholder Return (rTSR) | Aon |
| BridgeBio Pharma, Inc. | 135% | RSU 50 · PSU 35 · Options 15 | No | Aon Talent Solutions |
| Celldex Therapeutics, Inc. | 100% | Options 100 | not disclosed | Aon (Human Capital Solutions practice, a division of Aon plc) |
| CG Oncology, Inc. | 100% | Options 72 · PSU 28 | No | Pay Governance |
| Corcept Therapeutics Incorporated | Dr. Belanoff: 100%; Dr. Guyer: 120%; Mr. Maduck: 80%; Mr. Mokari: 100%; Mr. Robb: 100%% | Stock Options 100 | not disclosed | not disclosed |
| Crinetics Pharmaceuticals, Inc. | not disclosed | Options 70 · RSU 30 | not disclosed | Pearl Meyer |
| Cytokinetics, Incorporated | 120% | RSU 50 · Options 50 | not disclosed | Aon Human Capital Solutions |
| Day One Biopharmaceuticals, Inc. | 123%% | Stock Options 50 · RSUs 50 | not disclosed | Compensia Inc. |
| Erasca, Inc. | 120% | Options 100 | not disclosed | Alpine Rewards, LLC |
| IDEAYA Biosciences, Inc. | 90% | Options 100 | not disclosed | Aon (Aon plc, Talent Solutions practice) |
| IGM Biosciences, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Immunome, Inc. | 150% | Options 100 | not disclosed | Aon |
| Immunovant, Inc. | 110% | not disclosed | No | Compensia |
| Iovance Biotherapeutics, Inc. | 60% | not disclosed | No | Haigh & Company |
| Kiniksa Pharmaceuticals, Ltd. | not disclosed | Option 50 · RSU 25 · PSU 25 | not disclosed | Compensia, Inc. |
| Kura Oncology, Inc. | 150% | not disclosed | No | Alpine Rewards |
| Nuvalent, Inc. | 120% | not disclosed | No | Alpine Rewards |
| Relay Therapeutics, Inc. | 100% | Option 100 | not disclosed | Aon's Human Capital Solutions practice, a division of Aon plc |
| Revolution Medicines, Inc. | 146% | Options 70 · RSU 30 | not disclosed | Compensia |
| SpringWorks Therapeutics, Inc. | 140% | not disclosed | Yes — Relative Total Shareholder Return (TSR) | Aon |
| Syndax Pharmaceuticals, Inc. | 150% | Options 34 · PSU 33 · RSU 33 | Yes — Company's three-year total shareholder return (TSR) as measured against the Nasdaq Biotechnology Index components TSRs | Aon |
| Tyra Biosciences, Inc. | not disclosed | Options 100 | not disclosed | Aon Rewards Solutions |
| Xencor, Inc. | 110% | Options 60 · RSU 40 | not disclosed | Aon |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Andrew Robbins | DEF 14A | 2026-04-23 | 0001193125-26-173834 | Section “2025 Summary Compensation Table”. As printed: 27,762,684. Filing ↗machine: r2 · c39 · span 369353–369363 |
| 2 | Section 01, Jessica Sachs | DEF 14A | 2026-04-23 | 0001193125-26-173834 | Section “2025 Summary Compensation Table”. As printed: 9,178,177. Filing ↗machine: r9 · c39 · span 382883–382892 |
| 3 | Section 01, John Robinson | DEF 14A | 2026-04-23 | 0001193125-26-173834 | Section “2025 Summary Compensation Table”. As printed: 9,150,297. Filing ↗machine: r16 · c39 · span 396407–396416 |
| 4 | Section 01, Cole Pinnow | DEF 14A | 2026-04-23 | 0001193125-26-173834 | Section “2025 Summary Compensation Table”. As printed: 8,839,548. Filing ↗machine: r13 · c39 · span 390868–390877 |
| 5 | Section 01, John Green | DEF 14A | 2026-04-23 | 0001193125-26-173834 | Section “2025 Summary Compensation Table”. As printed: 8,546,329. Filing ↗machine: r6 · c39 · span 377340–377349 |
| 6 | Section 03, Jessica Sachs RSU | DEF 14A | 2026-04-23 | 0001193125-26-173834 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t82 · r17 · c54 · span 463294–463303 |
| 7 | Section 03, John Green OPTION | DEF 14A | 2026-04-23 | 0001193125-26-173834 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t82 · r11 · c54 · span 442490–442499 |
| 8 | Section 03, Andrew Robbins OPTION | DEF 14A | 2026-04-23 | 0001193125-26-173834 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t82 · r6 · c54 · span 425229–425238 |
| 9 | Section 03, Cole Pinnow PSU | DEF 14A | 2026-04-23 | 0001193125-26-173834 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t82 · r25 · c54 · span 491019–491028 |
| 10 | Section 03, John Green PSU | DEF 14A | 2026-04-23 | 0001193125-26-173834 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t82 · r10 · c54 · span 439074–439083 |
| 11 | Section 03, John Robinson OPTION | DEF 14A | 2026-04-23 | 0001193125-26-173834 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t82 · r19 · c54 · span 470290–470299 |
| 12 | Section 03, John Green RSU | DEF 14A | 2026-04-23 | 0001193125-26-173834 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t82 · r12 · c54 · span 445915–445924 |
| 13 | Section 03, John Robinson RSU | DEF 14A | 2026-04-23 | 0001193125-26-173834 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t82 · r22 · c54 · span 480549–480558 |
| 14 | Section 03, John Robinson PSU | DEF 14A | 2026-04-23 | 0001193125-26-173834 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t76 · r5 · c4 · span 343386–343393 |
| 15 | Section 03, Andrew Robbins PSU | DEF 14A | 2026-04-23 | 0001193125-26-173834 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t82 · r5 · c54 · span 421787–421796 |
| 16 | Section 03, Cole Pinnow RSU | DEF 14A | 2026-04-23 | 0001193125-26-173834 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t82 · r27 · c54 · span 497910–497919 |
| 17 | Section 03, Jessica Sachs OPTION | DEF 14A | 2026-04-23 | 0001193125-26-173834 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t82 · r14 · c54 · span 452960–452969 |
| 18 | Section 03, Jessica Sachs PSU | DEF 14A | 2026-04-23 | 0001193125-26-173834 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t76 · r4 · c4 · span 342508–342515 |
| 19 | Section 03, Andrew Robbins RSU | DEF 14A | 2026-04-23 | 0001193125-26-173834 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t82 · r7 · c54 · span 428680–428689 |
| 20 | Section 03, Cole Pinnow OPTION | DEF 14A | 2026-04-23 | 0001193125-26-173834 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t82 · r26 · c54 · span 494460–494469 |
| 21 | Section 03, John Green OPTION | DEF 14A | 2026-04-23 | 0001193125-26-173834 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t82 · r9 · c54 · span 435656–435665 |
| 22 | Section 03, Cole Pinnow OPTION | DEF 14A | 2026-04-23 | 0001193125-26-173834 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t82 · r24 · c54 · span 487576–487585 |
| 23 | Section 03, John Robinson OPTION | DEF 14A | 2026-04-23 | 0001193125-26-173834 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t82 · r21 · c54 · span 477124–477133 |
| 24 | Section 03, Jessica Sachs OPTION | DEF 14A | 2026-04-23 | 0001193125-26-173834 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t82 · r16 · c54 · span 459844–459853 |
| 25 | Section 03, Andrew Robbins OPTION | DEF 14A | 2026-04-23 | 0001193125-26-173834 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t82 · r4 · c54 · span 418342–418351 |
| 26 | Section 07, pay ratio | DEF 14A | 2026-04-23 | 0001193125-26-173834 | Section “CEO Pay Ratio”. As printed: 95 : 1. Filing ↗ |
| 27 | Section 08, Peter Harwin | DEF 14A | 2026-04-23 | 0001193125-26-173834 | Section “Director Compensation”. As printed: 277,115. Filing ↗machine: t39 · r5 · c14 · span 202390–202397 |
| 28 | Section 08, Todd Shegog | DEF 14A | 2026-04-23 | 0001193125-26-173834 | Section “Director Compensation”. As printed: 257,115. Filing ↗machine: t39 · r8 · c14 · span 205906–205913 |
| 29 | Section 08, Arlene M. Morris | DEF 14A | 2026-04-23 | 0001193125-26-173834 | Section “Director Compensation”. As printed: 254,615. Filing ↗machine: t39 · r6 · c14 · span 203556–203563 |
| 30 | Section 08, Chris Cain | DEF 14A | 2026-04-23 | 0001193125-26-173834 | Section “Director Compensation”. As printed: 252,115. Filing ↗machine: t39 · r3 · c14 · span 199977–199984 |
| 31 | Section 08, Karen Ferrante | DEF 14A | 2026-04-23 | 0001193125-26-173834 | Section “Director Compensation”. As printed: 247,115. Filing ↗machine: t39 · r4 · c14 · span 201147–201154 |
| 32 | Section 08, Matthew E. Ros | DEF 14A | 2026-04-23 | 0001193125-26-173834 | Section “Director Compensation”. As printed: 244,615. Filing ↗machine: t39 · r7 · c14 · span 204745–204752 |
| 33 | Section 08, Andrew Robbins | DEF 14A | 2026-04-23 | 0001193125-26-173834 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 34 | Section 02, Andrew Robbins 2026-05-19 | Form 4 | 2026-05-21 | 0001193125-26-234578 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Andrew Robbins 2026-05-19 | Form 4 | 2026-05-21 | 0001193125-26-234578 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Matthew E. Ros 2026-06-09 | Form 4 | 2026-06-11 | 0001193125-26-267666 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Todd Shegog 2026-06-09 | Form 4 | 2026-06-11 | 0001193125-26-267670 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Chris Cain 2026-06-09 | Form 4 | 2026-06-11 | 0001193125-26-267662 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Karen Ferrante 2026-06-09 | Form 4 | 2026-06-11 | 0001193125-26-267663 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Arlene M. Morris 2026-06-09 | Form 4 | 2026-06-11 | 0001193125-26-267667 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Peter Harwin 2026-06-09 | Form 4 | 2026-06-11 | 0001193125-26-267665 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Karen Ferrante 2026-07-01 | Form 4 | 2026-07-06 | 0001193125-26-296249 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Arlene M. Morris 2026-08-27 | Form 4 | 2026-08-31 | 0001193125-26-377001 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Arlene M. Morris 2026-08-27 | Form 4 | 2026-08-31 | 0001193125-26-377001 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Arlene M. Morris 2026-08-27 | Form 4 | 2026-08-31 | 0001193125-26-377001 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Arlene M. Morris 2026-08-27 | Form 4 | 2026-08-31 | 0001193125-26-377001 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Arlene M. Morris 2026-08-27 | Form 4 | 2026-08-31 | 0001193125-26-377001 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Arlene M. Morris 2026-08-27 | Form 4 | 2026-08-31 | 0001193125-26-377001 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Karen Ferrante 2026-10-01 | Form 4 | 2026-10-05 | 0001193125-26-414218 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 06, 2026 vote | Form 8-K | 2026-06-11 | 0001193125-26-267566 | Item 5.07 · say-on-pay result. As reported: 90.24% (votes for as printed: 129,183,846). Filing ↗ |
| 51 | Section 06, 2025 vote | Form 8-K | 2025-06-05 | 0001193125-25-135337 | Item 5.07 · say-on-pay result. As reported: 99.11% (votes for as printed: 89,797,699). Filing ↗ |
| 52 | Section 06, 2024 vote | Form 8-K | 2024-06-05 | 0001193125-24-155116 | Item 5.07 · say-on-pay result. As reported: 91.18% (votes for as printed: 69,604,506). Filing ↗ |
| 53 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 54 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 55 | Section 09b board cost (computed) | Computed | — | — | Cash 425,000 + equity 0 + all other 0 = 425,000, summed across the director compensation table rows.machine: formula: Σ = 425,000 |
| 56 | Cogent Biosciences, Inc. (subject), Section 10b CEO total | DEF 14A | 2026-04-23 | 0001193125-26-173834 | CEO total compensation as printed in Cogent Biosciences, Inc.'s own proxy. As printed: 27,762,684. Filing ↗machine: r2 · c39 · span 369353–369363 |
| 57 | Immunovant, Inc., Section 10b CEO total | DEF 14A | 2026-07-22 | 0001764013-26-000092 | CEO total compensation as printed in Immunovant, Inc.'s own proxy. As printed: 20,158,767. Filing ↗machine: span 465716–465726 |
| 58 | SpringWorks Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2025-04-04 | 0001104659-25-032187 | CEO total compensation as printed in SpringWorks Therapeutics, Inc.'s own proxy. As printed: 16,153,317. Filing ↗machine: r1 · c47 · span 623184–623194 |
| 59 | Corcept Therapeutics Incorporated, Section 10b CEO total | DEF 14A | 2026-04-17 | 0001628280-26-025735 | CEO total compensation as printed in Corcept Therapeutics Incorporated's own proxy. As printed: 15,303,551. Filing ↗machine: span 283504–283514 |
| 60 | BridgeBio Pharma, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001140361-26-016723 | CEO total compensation as printed in BridgeBio Pharma, Inc.'s own proxy. As printed: 14,944,585. Filing ↗machine: r2 · c21 · span 527521–527531 |
| 61 | Revolution Medicines, Inc., Section 10b CEO total | DEF 14A | 2026-04-27 | 0001193125-26-182453 | CEO total compensation as printed in Revolution Medicines, Inc.'s own proxy. As printed: 14,672,390. Filing ↗machine: r2 · c27 · span 382608–382618 |
| 62 | Blueprint Medicines Corporation, Section 10b CEO total | DEF 14A | 2025-04-24 | 0001558370-25-005415 | CEO total compensation as printed in Blueprint Medicines Corporation's own proxy. As printed: 13,477,004. Filing ↗machine: span 1101152–1101162 |
| 63 | CG Oncology, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177395 | CEO total compensation as printed in CG Oncology, Inc.'s own proxy. As printed: 11,928,401. Filing ↗machine: r2 · c8 · span 509631–509641 |
| 64 | Cytokinetics, Incorporated, Section 10b CEO total | DEF 14A | 2026-04-17 | 0001140361-26-015364 | CEO total compensation as printed in Cytokinetics, Incorporated's own proxy. As printed: 11,881,456. Filing ↗machine: r2 · c25 · span 777093–777103 |
| 65 | Crinetics Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001658247-26-000030 | CEO total compensation as printed in Crinetics Pharmaceuticals, Inc.'s own proxy. As printed: 11,628,959. Filing ↗machine: r2 · c48 · span 589450–589460 |
| 66 | Nuvalent, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001861560-26-000013 | CEO total compensation as printed in Nuvalent, Inc.'s own proxy. As printed: 11,393,602. Filing ↗machine: r2 · c14 · span 689237–689247 |
| 67 | Apellis Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2025-04-23 | 0000950170-25-056966 | CEO total compensation as printed in Apellis Pharmaceuticals, Inc.'s own proxy. As printed: 10,957,451. Filing ↗machine: r2 · c25 · span 951555–951565 |
| 68 | Kiniksa Pharmaceuticals, Ltd., Section 10b CEO total | DEF 14A | 2026-04-16 | 0001104659-26-044410 | CEO total compensation as printed in Kiniksa Pharmaceuticals, Ltd.'s own proxy. As printed: 10,782,661. Filing ↗ |
| 69 | Arcus Biosciences, Inc., Section 10b CEO total | DEF 14A | 2026-04-21 | 0001724521-26-000025 | CEO total compensation as printed in Arcus Biosciences, Inc.'s own proxy. As printed: 9,656,813. Filing ↗machine: r2 · c48 · span 403740–403749 |
| 70 | IDEAYA Biosciences, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191501 | CEO total compensation as printed in IDEAYA Biosciences, Inc.'s own proxy. As printed: 9,512,640. Filing ↗machine: r2 · c14 · span 627310–627319 |
| 71 | Amicus Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2025-04-24 | 0001140361-25-015479 | CEO total compensation as printed in Amicus Therapeutics, Inc.'s own proxy. As printed: 8,526,943. Filing ↗machine: r2 · c25 · span 736126–736136 |
| 72 | Immunome, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001140361-26-016685 | CEO total compensation as printed in Immunome, Inc.'s own proxy. As printed: 7,682,601. Filing ↗machine: r2 · c21 · span 416484–416493 |
| 73 | Syndax Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001193125-26-197859 | CEO total compensation as printed in Syndax Pharmaceuticals, Inc.'s own proxy. As printed: 7,089,213. Filing ↗machine: span 936322–936331 |
| 74 | Day One Biopharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2025-04-11 | 0001140361-25-013462 | CEO total compensation as printed in Day One Biopharmaceuticals, Inc.'s own proxy. As printed: 6,560,577. Filing ↗machine: r2 · c21 · span 526324–526333 |
| 75 | Arvinas, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001628280-26-028156 | CEO total compensation as printed in Arvinas, Inc.'s own proxy. As printed: 6,534,127. Filing ↗machine: t20 · r3 · c22 · span 471921–471930 |
| 76 | Bicycle Therapeutics plc, Section 10b CEO total | DEF 14A | 2026-04-22 | 0001104659-26-046806 | CEO total compensation as printed in Bicycle Therapeutics plc's own proxy. As printed: 6,341,473. Filing ↗machine: t83 · r5 · c14 · span 491024–491033 |
| 77 | Allogene Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001628280-26-028948 | CEO total compensation as printed in Allogene Therapeutics, Inc.'s own proxy. As printed: 6,136,093. Filing ↗machine: r2 · c54 · span 451014–451023 |
| 78 | AnaptysBio, Inc., Section 10b CEO total | DEF 14A | 2026-06-29 | 0001193125-26-288408 | CEO total compensation as printed in AnaptysBio, Inc.'s own proxy. As printed: 6,133,943. Filing ↗machine: span 694406–694415 |
| 79 | Tyra Biosciences, Inc., Section 10b CEO total | DEF 14A | 2026-04-17 | 0001193125-26-160360 | CEO total compensation as printed in Tyra Biosciences, Inc.'s own proxy. As printed: 5,566,997. Filing ↗machine: r2 · c23 · span 216822–216831 |
| 80 | Xencor, Inc., Section 10b CEO total | DEF 14A | 2026-04-27 | 0001326732-26-000031 | CEO total compensation as printed in Xencor, Inc.'s own proxy. As printed: 5,521,205. Filing ↗machine: t32 · r3 · c19 · span 631325–631334 |
| 81 | Celldex Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001104659-26-050884 | CEO total compensation as printed in Celldex Therapeutics, Inc.'s own proxy. As printed: 5,366,709. Filing ↗machine: r1 · c54 · span 1024857–1024866 |
| 82 | Kura Oncology, Inc., Section 10b CEO total | DEF 14A | 2026-04-10 | 0001193125-26-151335 | CEO total compensation as printed in Kura Oncology, Inc.'s own proxy. As printed: 4,735,016. Filing ↗machine: span 1018180–1018189 |
| 83 | Relay Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-186929 | CEO total compensation as printed in Relay Therapeutics, Inc.'s own proxy. As printed: 4,646,454. Filing ↗machine: r2 · c29 · span 660153–660162 |
| 84 | Erasca, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187361 | CEO total compensation as printed in Erasca, Inc.'s own proxy. As printed: 4,298,838. Filing ↗machine: r2 · c31 · span 221524–221533 |
| 85 | IGM Biosciences, Inc., Section 10b CEO total | DEF 14A | 2024-04-26 | 0000950170-24-049091 | CEO total compensation as printed in IGM Biosciences, Inc.'s own proxy. As printed: 3,207,328. Filing ↗machine: r2 · c21 · span 824822–824831 |
| 86 | Iovance Biotherapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-050458 | CEO total compensation as printed in Iovance Biotherapeutics, Inc.'s own proxy. As printed: 1,888,175. Filing ↗machine: r6 · c16 · span 797910–797919 |
| 87 | Section 10a, SpringWorks Therapeutics, Inc. reciprocity | DEF 14A | — | 0001104659-25-032187 | SpringWorks Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Cogent Biosciences, Inc.. Filing ↗ |
| 88 | Section 10a, Syndax Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001193125-26-197859 | Syndax Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Cogent Biosciences, Inc.. Filing ↗ |
| 89 | Section 10a, IDEAYA Biosciences, Inc. reciprocity | DEF 14A | — | 0001193125-26-191501 | IDEAYA Biosciences, Inc. names Cogent Biosciences, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 90 | Section 10a, Revolution Medicines, Inc. reciprocity | DEF 14A | — | 0001193125-26-182453 | Revolution Medicines, Inc.'s most recent proxy was read; its disclosed peer group does not include Cogent Biosciences, Inc.. Filing ↗ |
| 91 | Section 10a, Cytokinetics, Incorporated reciprocity | DEF 14A | — | 0001140361-26-015364 | Cytokinetics, Incorporated's most recent proxy was read; its disclosed peer group does not include Cogent Biosciences, Inc.. Filing ↗ |
| 92 | Section 10a, Blueprint Medicines Corporation reciprocity | DEF 14A | — | 0001558370-25-005415 | Blueprint Medicines Corporation's most recent proxy was read; its disclosed peer group does not include Cogent Biosciences, Inc.. Filing ↗ |
| 93 | Section 10a, Allogene Therapeutics, Inc. reciprocity | DEF 14A | — | 0001628280-26-028948 | Allogene Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Cogent Biosciences, Inc.. Filing ↗ |
| 94 | Section 10a, AnaptysBio, Inc. reciprocity | DEF 14A | — | 0001193125-26-288408 | AnaptysBio, Inc.'s most recent proxy was read; its disclosed peer group does not include Cogent Biosciences, Inc.. Filing ↗ |
| 95 | Section 10a, Arvinas, Inc. reciprocity | DEF 14A | — | 0001628280-26-028156 | Arvinas, Inc. names Cogent Biosciences, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 96 | Section 10a, Bicycle Therapeutics plc reciprocity | DEF 14A | — | 0001558370-25-005258 | Bicycle Therapeutics plc names Cogent Biosciences, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 97 | Section 10a, Celldex Therapeutics, Inc. reciprocity | DEF 14A | — | 0001104659-26-050884 | Celldex Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Cogent Biosciences, Inc.. Filing ↗ |
| 98 | Section 10a, Day One Biopharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001140361-25-013462 | Day One Biopharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Cogent Biosciences, Inc.. Filing ↗ |
| 99 | Section 10a, IGM Biosciences, Inc. reciprocity | DEF 14A | — | 0000950170-24-049091 | IGM Biosciences, Inc.'s most recent proxy was read; its disclosed peer group does not include Cogent Biosciences, Inc.. Filing ↗ |
| 100 | Section 10a, Iovance Biotherapeutics, Inc. reciprocity | DEF 14A | — | 0001104659-26-050458 | Iovance Biotherapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Cogent Biosciences, Inc.. Filing ↗ |
| 101 | Section 10a, Kiniksa Pharmaceuticals, Ltd. reciprocity | DEF 14A | — | 0001104659-26-044410 | Kiniksa Pharmaceuticals, Ltd.'s most recent proxy was read; its disclosed peer group does not include Cogent Biosciences, Inc.. Filing ↗ |
| 102 | Section 10a, Kura Oncology, Inc. reciprocity | DEF 14A | — | 0001193125-26-151335 | Kura Oncology, Inc. names Cogent Biosciences, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 103 | Section 10a, Nuvalent, Inc. reciprocity | DEF 14A | — | 0001861560-26-000013 | Nuvalent, Inc.'s most recent proxy was read; its disclosed peer group does not include Cogent Biosciences, Inc.. Filing ↗ |
| 104 | Section 10a, Relay Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-186929 | Relay Therapeutics, Inc. names Cogent Biosciences, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 105 | Section 10a, Xencor, Inc. reciprocity | DEF 14A | — | 0001326732-26-000031 | Xencor, Inc.'s most recent proxy was read; its disclosed peer group does not include Cogent Biosciences, Inc.. Filing ↗ |
| 106 | Section 10a, Amicus Therapeutics, Inc. reciprocity | DEF 14A | — | 0001140361-25-015479 | Amicus Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Cogent Biosciences, Inc.. Filing ↗ |
| 107 | Section 10a, Apellis Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0000950170-25-056966 | Apellis Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Cogent Biosciences, Inc.. Filing ↗ |
| 108 | Section 10a, BridgeBio Pharma, Inc. reciprocity | DEF 14A | — | 0001140361-26-016723 | BridgeBio Pharma, Inc.'s most recent proxy was read; its disclosed peer group does not include Cogent Biosciences, Inc.. Filing ↗ |
| 109 | Section 10a, CG Oncology, Inc. reciprocity | DEF 14A | — | 0001193125-26-177395 | CG Oncology, Inc.'s most recent proxy was read; its disclosed peer group does not include Cogent Biosciences, Inc.. Filing ↗ |
| 110 | Section 10a, Crinetics Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001658247-26-000030 | Crinetics Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Cogent Biosciences, Inc.. Filing ↗ |
| 111 | Section 10a, Immunovant, Inc. reciprocity | DEF 14A | — | 0001764013-26-000092 | Immunovant, Inc.'s most recent proxy was read; its disclosed peer group does not include Cogent Biosciences, Inc.. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.
Get the Cogent Biosciences, Inc. Executive Compensation Report
$1,500